Evidence map›Paper›PMID 32829460›Full record

ArticleAnnals of hematology2021

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.

Ramona Wullenkord, Christian Reicherts, Jan-Henrik Mikesch, Julia Marx, Klaus Wethmar, Jörn Albring, Simon Call, Georg Lenz, Matthias Stelljes

Open access · hybridAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ramona WullenkordDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Christian ReichertsDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Jan-Henrik MikeschDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Julia MarxDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Klaus WethmarDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Jörn AlbringDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Simon CallDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Georg LenzDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Matthias StelljesDepartment of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. matthias.stelljes@ukmuenster.de.ORCID http://orcid.org/0000-0002-9331-5145
University of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunotherapy, AdoptiveAgedAntibodies, BispecificAntigens, CD19FemaleFlow CytometryHumansInotuzumab OzogamicinPrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceT-LymphocytesAntibodies, BispecificAntigens, CD19blinatumomabCD19 molecule, humanInotuzumab Ozogamicin

Identifiers

PMID32829460
PMCPMC7817557
OpenAlexW3081035421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.